BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 7970192)

  • 1. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
    Pérez-Otaño I; Oset C; Luquin MR; Herrero MT; Obeso JA; Del Río J
    Neurosci Lett; 1994 Jul; 175(1-2):121-5. PubMed ID: 7970192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
    Pifl C; Schingnitz G; Hornykiewicz O
    Neurosci Lett; 1988 Oct; 92(2):228-33. PubMed ID: 3263594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
    Schneider JS; Pope A; Simpson K; Taggart J; Smith MG; DiStefano L
    Science; 1992 May; 256(5058):843-6. PubMed ID: 1350379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.
    Fuxe K; Janson AM; Rosén L; Finnman UB; Tanganelli S; Morari M; Goldstein M; Agnati LF
    Exp Brain Res; 1992; 88(1):117-30. PubMed ID: 1347270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
    Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
    Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
    Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
    Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
    D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
    Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys.
    Pifl C; Hornykiewicz O
    Neurochem Int; 2006 Oct; 49(5):519-24. PubMed ID: 16698121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites.
    Johannessen JN; Sobotka TJ; Weise VK; Markey SP
    J Neurochem; 1991 Sep; 57(3):981-90. PubMed ID: 1677682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.
    Hadjiconstantinou M; Mariani AP; Neff NH
    Brain Res; 1989 Apr; 484(1-2):297-303. PubMed ID: 2565752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Bezard E; Dovero S; Prunier C; Ravenscroft P; Chalon S; Guilloteau D; Crossman AR; Bioulac B; Brotchie JM; Gross CE
    J Neurosci; 2001 Sep; 21(17):6853-61. PubMed ID: 11517273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
    Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions.
    Elsworth JD; Deutch AY; Redmond DE; Taylor JR; Sladek JR; Roth RH
    Neuroscience; 1989; 33(2):323-31. PubMed ID: 2622529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey.
    Irwin I; DeLanney LE; Forno LS; Finnegan KT; Di Monte DA; Langston JW
    Brain Res; 1990 Oct; 531(1-2):242-52. PubMed ID: 1981162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
    Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
    Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys.
    Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH
    Brain Res; 1990 Apr; 513(2):320-4. PubMed ID: 2350702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
    Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T
    Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
    Albanese A; Granata R; Gregori B; Piccardi MP; Colosimo C; Tonali P
    Neuroscience; 1993 Aug; 55(3):823-32. PubMed ID: 8105418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.